Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global HIV Drugs Market: By Drug Class: Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, Others; By Distribution Channel; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global HIV Drugs Market Outlook
The global HIV drugs market stood at a value of USD 24.3 billion in 2020. The market is expected to reach USD 22.1 billion by 2026 while declining at a CAGR of 2.4% over the forecast period of 2021-2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of drug class, the nucleoside reverse transcriptase inhibitors segment accounted for the majority of the market share in 2020. Based on the distribution channel, the hospital pharmacies segment dominated the global HIV drugs market in 2020 and is estimated to retain its dominance over the forecast period of 2021-2026.
Regionally, North America is expected to hold the largest market share in 2020. The regional growth is attributed to the increased number of research and development initiatives for new drug launches, a well-established healthcare system, and the growing adoption of advanced treatment options from HIV infected population. However, the majority of people with HIV are encountered in low as well as middle-income countries. In 2018, there were 20.6 million people with HIV (57%) in eastern and southern Africa, owing to this, the Middle East and Africa is anticipated to register the highest CAGR over the forecast period.
Properties and Applications
Human Immunodeficiency Virus (HIV) is a virus that causes a chronic and life-threatening disease that can be transferred from one person to another through blood-to-blood and sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease across the world has positively impacted the demand for HIV drugs. These drugs prevent the multiplication of HIV and make the immune system strong enough to resist certain infections, thereby reducing the risk of transmission.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aids in increasing the number of CD4+ cells and decreasing the amount of virus in the blood.
On the basis of drug class, the global HIV drugs market is segmented into:
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Others
Based on the distribution channel, the industry can be segregated into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
The EMR report looks into the regional markets in the global HIV drugs market like North America, the Asia Pacific, Europe, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
According to the estimates by the World Health Organization (WHO), 37.9 million people are living with HIV, and nearly 2 million people become newly infected at the end of 2018. The growing population density of HIV infected people has been instrumental in the development and introduction of HIV drugs. Besides, the market is also influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of HIV. Moreover, the introduction of generic drugs acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs.
Additionally, many international organizations are providing funds to research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions. Owing to the aforementioned factors, the demand for HIV drugs is expected to augment over the forecast period. However, the cost of antiretroviral drugs is relatively high, and patients without healthcare coverage find it extremely difficult to pay, which is likely to restrain the market growth up to some extent, contributing to its negative growth rate. The side effects of these drugs is also preventing the growth of the market with many of the patients giving up the medications due to these harsh side effects, which can include hyperlipidemia, osteopenia, lipodystrophy, and osteoporosis The market is also expected to decline in the forecast period due to the rising awareness about how to prevent the spread of the disease and the upcoming patent expirations.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global HIV drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Boehringer Ingelheim International GmbH
- ViiV Healthcare
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Cipla Inc.
- Johnson & Johnson Services, Inc.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2016-2020 |
| Forecast Period | 2021-2026 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Distribution Channel, Region |
| Breakup by Drug Class | Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Products, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Entry Inhibitors — CCR5 Co-Receptor Antagonist, Fusion Inhibitors, Others |
| Breakup by Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Boehringer Ingelheim International GmbH, ViiV Healthcare, Merck & Co., Inc, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Cipla Inc., Johnson & Johnson Services, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global HIV Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global HIV Drugs Historical Market (2016-2020)
8.3 Global HIV Drugs Market Forecast (2021-2026)
8.4 Global HIV Drugs Market by Drug Class
8.4.1 Nucleoside Reverse Transcriptase Inhibitors
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2016-2020)
8.4.1.3 Forecast Trend (2021-2026)
8.4.2 Multi-Class Combination Products
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2016-2020)
8.4.2.3 Forecast Trend (2021-2026)
8.4.3 Protease Inhibitors
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2016-2020)
8.4.3.3 Forecast Trend (2021-2026)
8.4.4 HIV Integrase Strand Transfer Inhibitors
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2016-2020)
8.4.4.3 Forecast Trend (2021-2026)
8.4.5 Non-Nucleoside Reverse Transcriptase Inhibitors
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2016-2020)
8.4.5.3 Forecast Trend (2021-2026)
8.4.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2016-2020)
8.4.6.3 Forecast Trend (2021-2026)
8.4.7 Fusion Inhibitors
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2016-2020)
8.4.7.3 Forecast Trend (2021-2026)
8.4.8 Others
8.5 Global HIV Drugs Market by Distribution Channel
8.5.1 Hospital Pharmacies
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2016-2020)
8.5.1.3 Forecast Trend (2021-2026)
8.5.2 Retail Pharmacies
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2016-2020)
8.5.2.3 Forecast Trend (2021-2026)
8.5.3 Online Pharmacies
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2016-2020)
8.5.3.3 Forecast Trend (2021-2026)
8.5.4 Others
8.6 Global HIV Drugs Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2016-2020)
9.1.2 Forecast Trend (2021-2026)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2016-2020)
9.2.2 Forecast Trend (2021-2026)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2016-2020)
9.3.2 Forecast Trend (2021-2026)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2016-2020)
9.4.2 Forecast Trend (2021-2026)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2016-2020)
9.5.2 Forecast Trend (2021-2026)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyers Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Company Profiles
12.3.1 Boehringer Ingelheim International GmbH
12.3.1.1 Company Overview
12.3.1.2 Product Portfolio
12.3.1.3 Demographic Reach and Achievements
12.3.1.4 Certifications
12.3.2 ViiV Healthcare
12.3.2.1 Company Overview
12.3.2.2 Product Portfolio
12.3.2.3 Demographic Reach and Achievements
12.3.2.4 Certifications
12.3.3 Merck & Co., Inc
12.3.3.1 Company Overview
12.3.3.2 Product Portfolio
12.3.3.3 Demographic Reach and Achievements
12.3.3.4 Certifications
12.3.4 F. Hoffmann-La Roche Ltd.
12.3.4.1 Company Overview
12.3.4.2 Product Portfolio
12.3.4.3 Demographic Reach and Achievements
12.3.4.4 Certifications
12.3.5 Gilead Sciences, Inc.
12.3.5.1 Company Overview
12.3.5.2 Product Portfolio
12.3.5.3 Demographic Reach and Achievements
12.3.5.4 Certifications
12.3.6 Cipla Inc.
12.3.6.1 Company Overview
12.3.6.2 Product Portfolio
12.3.6.3 Demographic Reach and Achievements
12.3.6.4 Certifications
12.3.7 Johnson & Johnson Services, Inc.
12.3.7.1 Company Overview
12.3.7.2 Product Portfolio
12.3.7.3 Demographic Reach and Achievements
12.3.7.4 Certifications
12.3.8 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global HIV Drugs Market: Key Industry Highlights, 2016 and 2026
2. Global HIV Drugs Historical Market: Breakup by Drug Class (USD Billion), 2016-2020
3. Global HIV Drugs Market Forecast: Breakup by Drug Class (USD Billion), 2021-2026
4. Global HIV Drugs Historical Market: Breakup by Distribution Channel (USD Billion), 2016-2020
5. Global HIV Drugs Market Forecast: Breakup by Distribution Channel (USD Billion), 2021-2026
6. Global HIV Drugs Historical Market: Breakup by Region (USD Billion), 2016-2020
7. Global HIV Drugs Market Forecast: Breakup by Region (USD Billion), 2021-2026
8. North America HIV Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
9. North America HIV Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
10. Europe HIV Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
11. Europe HIV Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
12. Asia Pacific HIV Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
13. Asia Pacific HIV Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
14. Latin America HIV Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
15. Latin America HIV Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
16. Middle East and Africa HIV Drugs Historical Market: Breakup by Country (USD Billion), 2016-2020
17. Middle East and Africa HIV Drugs Market Forecast: Breakup by Country (USD Billion), 2021-2026
18. Global HIV Drugs Market Structure
Key Questions Answered in the Report
In 2020, the global HIV drugs market attained a value of nearly USD 24.3 billion.
The market is projected to decline at a CAGR of 2.4% between 2021 and 2026.
The market is estimated to reach about USD 22.1 billion by 2026.
The market growth is being constrained by the high cost of the treatment and the side effects of the drugs, along with the upcoming threat of patent expirations and the growing awareness about how to effectively curb the spread of the disease.
The key market trend informing the HIV drugs market includes the emerging provision of research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Nucleoside reverse transcriptase inhibitors are the leading drug class of HIV drugs in the industry.
The distribution channel segment is led by hospital pharmacies.
The major players in the industry are Boehringer Ingelheim International GmbH, ViiV Healthcare, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Cipla Inc., and Johnson & Johnson Services, Inc., among others.
Analyst Review
The global HIV drugs market attained a value of USD 24.3 billion in 2020, driven by a growing population density of HIV infected people. Due to the high cost of antiretroviral drugs and rising awareness, the market is expected to witness a decline in the forecast period of 2021-2026, declining at a CAGR of 2.4%. The HIV drugs market is projected to reach USD 22.1 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its drug class, nucleoside reverse transcriptase inhibitors are the leading segment. On the basis of distribution channels, the hospital pharmacies sector accounts for the leading share in the industry. The major regional markets for HIV drugs are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, with North America accounting for the largest share of the market. The key players in the above market include Boehringer Ingelheim International GmbH, ViiV Healthcare, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Cipla Inc., Johnson & Johnson Services, Inc., and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global telmisartan market attained a value of about USD 3,574 million in 2020, driven by the rising cases of hypertension and cardiovascular diseases. Aided by the robustly growing pharmaceutical ...
The global doxorubicin market attained a value of about USD 1,075.90 million in 2020, driven by the rising cases of cancer worldwide. Aided by government investments in the pharmaceutical sector, the ...
The global radiopharmaceuticals market attained a value of about USD 4.3 billion, driven by rising applications in diagnostic and therapeutic segment. Aided by constant research and development and ri...
The global anticoagulants market is driven by the rising prevalence of various cardiovascular diseases. Aided by the growing adoption of safer and more efficient anticoagulants, the market is expected...
The global acne medication market attained a value of nearly USD 8.9 billion in 2020, driven by the rising prevalence of acne disorders and the growing advancements in developing acne treatment soluti...
NEWSLETTER